Altern Ther Health Med. 2023 Nov;29(8):255-261.
The purpose of this pilot study is to explore the difference in safety and effectiveness after stenting in patients with extracranial or intracranial vertebral artery stenosis.
The study involved 26 patients treated with stents for ≥70% stenosis between January 1, 2017, and September 8, 2020. The patients were divided into intracranial and extracranial groups based on the location of the target vessel stenosis. The incidence of stroke or death within 30 days, long-term recurrence of ischemic symptoms, and restenosis during follow-up were monitored.
Within 30 days, no stroke or death was observed in the 26 patients, During the follow-up period, the risk of recurrence of posterior circulation stroke or transient ischemic attack was 23.1% (6/26). Vascular-related complications were 5.6% vs. 12.5% (P = .529) in the intracranial vs. extracranial stenosis group. After 1 year, stroke or transient ischemic attack of posterior circulation was observed in 12.5% (1/8) vs. 16.7% (3/18) in the intracranial and extracranial stenosis group, respectively. The restenosis rate in the intracranial stenosis group was higher than the extracranial stenosis group (37.5% vs. 28.6%, P > .05). This trend was also found in the asymptomatic restenosis rate (25% vs. 7.1%, P = .527).
The study results showed that there was no significant difference in the safety and effectiveness after stenting in extracranial and intracranial vertebral artery stenosis, but intracranial vertebral artery stenosis has a low rate of symptomatic restenosis. Symptomatic restenosis may be an important problem that limits the efficacy of extracranial vertebral artery stenting.
本研究旨在探讨颅内外椎动脉狭窄患者支架置入术后的安全性和有效性差异。
本研究纳入了 2017 年 1 月 1 日至 2020 年 9 月 8 日期间因≥70%狭窄而行支架置入治疗的 26 例患者。根据靶血管狭窄部位,将患者分为颅内外组。监测两组患者术后 30 天内的卒中或死亡发生率、缺血症状的长期复发及随访期间的再狭窄率。
26 例患者术后 30 天内均未发生卒中或死亡。随访期间,后循环卒中或短暂性脑缺血发作的复发风险为 23.1%(6/26)。颅内组与颅外组血管相关并发症发生率分别为 5.6%和 12.5%(P =.529)。术后 1 年,颅内组和颅外组后循环卒中或短暂性脑缺血发作的发生率分别为 12.5%(1/8)和 16.7%(3/18)。颅内组再狭窄率高于颅外组(37.5% vs. 28.6%,P >.05)。无症状再狭窄率也存在同样的趋势(25% vs. 7.1%,P =.527)。
研究结果表明,颅内外椎动脉狭窄患者支架置入术后的安全性和有效性无显著差异,但颅内椎动脉狭窄的症状性再狭窄率较低。症状性再狭窄可能是限制颅外椎动脉支架置入疗效的一个重要问题。